Current Trend of Prescribing Anticoagulant and Antiviral Drugs in the Treatment of COVID- 19 Patients in a Corona Dedicated Hospital in Khulna
DOI:
https://doi.org/10.3329/mediscope.v10i1.65402Keywords:
Enoxaparin, Remdesivir, COVID-19Abstract
Background: Thrombo-embolic incidence secondary to COVID-19 with increased mortality rate has become a global concern. Anticoagulants are widely used to prevent mortality. On the other hand, antiviral therapy has a potential effect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Aims & objectives: This study aims to assess the use pattern of anticoagulant and antiviral drugs against COVID-19.
Methods: This is an observational cross-sectional study where two hundred COVID-19-positive patients of both sexes and different age groups who received anticoagulants and antivirals were recruited. All data were compiled in a Microsoft excel spreadsheet. Results were expressed in frequency & percentage.
Results: Out of 200 patients, there were 115 males (57.5%) & 85 females (42.5%); the majority (56%) belonged to the age group between 30 to 60 years. Clinically, patients were categorized into mild (25%), moderate (32%), severe (37.5%), and critical (5.5%) cases. In this study, 88% of patients received low molecular weight heparin (enoxaparin) in a prophylactic dose and 12% of patients received in a therapeutic dose. Among the antivirals, remdesivir (84%) followed by favipiravir (16%) were the most commonly prescribed drugs.
Conclusion: Anticoagulant (enoxaparin) and antiviral (remdesivir) drugs are frequently prescribed in the treatment of COVID-19 patients.
Mediscope 2023;10(1):10-16
Downloads
30
34
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Muhammad Ashraful Kabir, Baishakhi Islam, Tasnim Rahman, Tamanna Jannat, Jesmin Zahan Tuli, Abdullah Al Faroque
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in the Mediscope agree to the following terms that:
- Authors retain copyright and grant Mediscope the right of first publication of the work.
Articles in Mediscope are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0. This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.